Skip to Content
Merck
  • Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma.

Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma.

Cell reports. Medicine (2021-10-09)
Jaime L Chao, Michael Korzinkin, Alex Zhavoronkov, Ivan V Ozerov, Matthew T Walker, Kathleen Higgins, Mark W Lingen, Evgeny Izumchenko, Peter A Savage
ABSTRACT

Immune suppression by CD4+FOXP3+ regulatory T (Treg) cells and tumor infiltration by CD8+ effector T cells represent two major factors impacting response to cancer immunotherapy. Using deconvolution-based transcriptional profiling of human papilloma virus (HPV)-negative oral squamous cell carcinomas (OSCCs) and other solid cancers, we demonstrate that the density of Treg cells does not correlate with that of CD8+ T cells in many tumors, revealing polarized clusters enriched for either CD8+ T cells or CD4+ Treg and conventional T cells. In a mouse model of carcinogen-induced OSCC characterized by CD4+ T cell enrichment, late-stage Treg cell ablation triggers increased densities of both CD4+ and CD8+ effector T cells within oral lesions. Notably, this intervention does not induce tumor regression but instead induces rapid emergence of invasive OSCCs via an effector T cell-dependent process. Thus, induction of a T cell-inflamed phenotype via therapeutic manipulation of Treg cells may trigger unexpected tumor-promoting effects in OSCC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CD3 antibody, Rabbit monoclonal, recombinant, expressed in proprietary host, clone SP162, affinity isolated antibody
Roche
DNase I, grade II, from bovine pancreas
Sigma-Aldrich
Diphtheria Toxin from Corynebacterium diphtheriae, lyophilized powder, Product is in unnicked form
Sigma-Aldrich
Phorbol 12-myristate 13-acetate, synthetic, ≥98.0% (TLC)